Bioxel Pharma Inc.

Bioxel Pharma Inc.

February 01, 2007 10:09 ET

International Pharmaceutical Executive to Augment Bioxel Board Expertise

SAINTE-FOY, QUEBEC--(CCNMatthews - Feb. 1, 2007) - Dr. Andre P. Boulet, Chairman of the Board of Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, is pleased to announce that Dr. Rafick G. Henein has agreed to join the Company's Board of Directors. Dr. Henein will initially sit on the Board of Bioxel as an observer starting February 1, 2007. His nomination will be subject to shareholders' ratification at the Company's forthcoming annual general meeting.

Dr. Henein has held various executive positions in the pharmaceutical industry in the Middle East, Europe, Canada and the United States. In Canada, he started his career at Ayerst Laboratories Inc. in 1971 and served as Senior Vice President, Plant and Distribution Operations from 1983 to 1988. He then joined Novopharm Limited (Canada), first as Executive Vice President and, subsequently as President and Chief Operating Officer before being named President and Chief Executive Officer of Novopharm International. In 1997, Dr. Henein joined IVAX Pharmaceuticals, Inc., a leading generic company headquartered in Miami, Florida and served as its President and Chief Executive Officer until its acquisition last year by Teva to form one of the largest pharmaceutical generic companies in the world.

"Dr. Henein's diverse and exceptional experience of the pharmaceutical generic industry, will be of significant benefit to Bioxel's international development and growth. We are confident that his guidance and vision will further augment the Board's ability to enhance shareholder value," said Dr. Boulet.

Dr. Henein holds a Ph.D. in pharmaceutical technology from the Academy of Sciences of Hungary and a M.Sc. in pharmaceutical sciences from Budapest University in Hungary. He also has a MBA and a Diploma in Management from McGill University. Dr. Henein is a member of the Ontario College of Pharmacists and the Order of Pharmacists of Quebec.


Bioxel Pharma Inc. is a biopharmaceutical company, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

Contact Information

  • Bioxel Pharma Inc.
    Pascal Delmas, Pharm.D, MBA
    President and Chief Executive Officer